Sandoz launches authorized generic version of Diovan® in the US

Princeton, New Jersey, July 8, 2014 – Sandoz today announced the US introduction of an authorized generic version of Diovan® (valsartan) tablets for the treatment of high blood pressure (HBP).

​This launch follows the Sandoz US introduction of an authorized generic version of Diovan HCT® (valsartan and hydrochlorothiazide) in 2012. Both Diovan and Diovan HCT are marketed in the US by Novartis Pharmaceuticals Corporation (NPC) and are indicated for the treatment of HBP, a condition that affects approximately one in three US adults.1,2

“We are pleased to offer …

/by

Sandoz brings together key French stakeholders to discuss biosimilars

Sandoz, the global leader in biosimilars, recently hosted an event in Paris for key stakeholders to discuss strategic issues impacting biosimilars and help them better understand their vital role in the success of these important therapies in France.

Read more

/by

Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide

  • Sandoz makes long-term commitment to support UN initiative on child mortality
  • Commitment to UN Every Newborn Action Plan involves development and supply of recommended WHO formulation for treating childhood pneumonia
  • Pneumonia is the leading cause of death globally among children under five

Holzkirchen, June 30, 2014 – Sandoz today announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation, as part of the United Nations’ new Every Newborn Action Plan.

The …

/by

Sandoz launches Airflusal® Forspiro® in Sweden, further driving patient access to innovative new respiratory inhaler

  • Sweden is fourth European country to launch Sandoz’s award-winning new inhaler for patients with asthma and COPD
  • Sandoz Sweden launches both 50-500 and 50-250 microgram dosage forms, following national marketing authorization earlier this year
  • Airflusal Forspiro offers proven combination of salmeterol and fluticasone propionate in an innovative new device, co-developed with patients

Holzkirchen, June 23, 2014: Sandoz today announced the launch in Sweden of Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or …

/by

Sandoz launches three new products in Japan, including authorized generics of valsartan and zoledronic acid

  • Sandoz Japan launches valsartan, the first authorized generic ARB in Japan. Sandoz also launches authorized generic of Zometa® for i.v. infusion 4mg/5mL and generic version of Preminent® Tablets LD

Tokyo, June 20, 2014 Sandoz announces today the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan® Tablets, zoledronic acid, a generic version of Novartis’ Zometa® for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent® Tablets LD.

Valsartan and …

/by

GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case

  • GlaxoSmithKline withdraws application for preliminary injunction on German marketing and distribution of Sandoz’s award-winning AirFluSal® Forspiro®
  • GSK application withdrawn shortly before Cologne Court of Appeals was due to rule in the case, restoring German patient access to AirFluSal
  • Sandoz continues to roll out its innovative and cost-effective respiratory inhaler, co-developed with patients, in Europe and beyond

Holzkirchen, June 16, 2014: Pharmaceutical company GlaxoSmithKline has withdrawn its application for a preliminary …

/by

Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market

  • French launch is latest milestone in roll-out of Sandoz respiratory portfolio – a key pillar of its strategy to bring differentiated generics to patients and payors worldwide
  • Mometasone Sandoz® is first French specialty generic medicine indicated for treatment of a respiratory condition together with an inhaler
  • Allergic rhinitis affects up to 25% of the population of Western Europe annually

Levallois-Perret, June 2, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, …

/by

Sandoz enhances strategic relationship with Upsher-Smith through marketing agreement for potassium chloride products

Princeton, New Jersey, June 3, 2014 – Sandoz today announced an agreement with Upsher-Smith to obtain exclusive US distribution rights for its branded potassium chloride line of products, Klor-Con®, and market them under the Sandoz name, enhancing its strategic relationship.

“This agreement expands and strengthens our current relationship with Upsher-Smith and helps us create a leading potassium chloride business,” said Peter Goldschmidt, President of Sandoz Inc. “With our extensive distribution system, we will be able to improve patient access to these products, …

/by

Sandoz associates join Novartis Community Partnership Day 2014

Holzkirchen, May 15, 2015 – More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day

Novartis associates across 55 countries engaged in local volunteer efforts to support their communities in celebration of the company’s annual Community Partnership Day (CPD).

May 8th of this year marked the 18th Community Partnership Day, commemorating the 1996 creation of Novartis as a global leader in healthcare.

There is strong participation from all Novartis divisions in 2014, including Sandoz. Here we feature some …

/by

Sandoz launches generic version of key anti-depressant Cipralex® in several European countries

Holzkirchen, June 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.

The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.

Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional …

/by